New Data From 2023 ESMO Congress Further Define the Evolving Role of ADCs in NSCLC
November 15th 2023With a plethora of data coming out of the 2023 European Society for Medical Oncology Congress, findings from multiple clinical trials examining antibody-drug conjugates in non–small cell lung cancer demonstrated encouraging antitumor activity and manageable safety profiles, including results from the phase 3 TROPION-Lung01 study, which evaluated datopotamab deruxtecan vs docetaxel in pretreated patients with advanced or metastatic disease.
Investigators Deliver Updates on Evolving Clinical Trials Evaluating ADCs in Lung Cancer
November 2nd 2023Melissa L. Johnson, MD, Terufumi Kato, MD, and Pasi A. Jänne, MD, PhD, present updates from the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.
Dr Passaro on the Significance of the TROPION-Lung05 Trial of Dato-DXd in NSCLC
November 1st 2023Antonio Passaro, MD, PhD, medical oncologist, Division of Thoracic Oncology, European Institute of Oncology, discusses the significance of data from the phase 2 TROPION-Lung05 trial of datopotamab deruxtecan in patients with non–small cell lung cancer.
Dr Liu on the Significance of T-DXd For Patients With HER2-Mutant NSCLC and Brain Metastases
October 31st 2023Stephen V. Liu, MD, discusses the significance of using fam-trastuzumab deruxtecan-nxki in patients with HER2-mutant non–small cell lung cancer and brain metastases according to pooled findings from exploratory analyses of the phase 2 DESTINY-Lung01 and DESTINY-Lung02 trials.
Dr Johnson on the Initial Efficacy of Ifinatamab Deruxtecan in Refractory SCLC
September 18th 2023Melissa L. Johnson, MD, discusses findings from a subgroup analysis of outcomes with ifinatamab deruxtecan in patients with refractory small cell lung cancer, which she presented at the 2023 IASLC World Conference on Lung Cancer.